Livtencity: Side Effects & Dosing

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Concise Prescribing Info

Contents

Maribavir

Indications/Uses

Adults & paed ≥12 yr weighing at least 35 kg w/ post-transplant cytomegalovirus (CMV) infection & disease resistant, refractory or intolerant to ≥1 prior therapies.

Click to view Livtencity detailed prescribing information

Dosage/Direction for Use

400 mg bid resulting in a daily dose of 800 mg. Individualised treatment duration based on clinical characteristics of each patient. Co-administration w/ carbamazepine 800 mg-1,200 mg bid. Co-administration w/ phenytoin or phenobarb 1,200 mg bid.

Click to view Livtencity detailed prescribing information

Overdosage

View Livtencity overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food: May disperse/crush or take tab as whole PO or as dispersed tab via nasogastric/orogastric tube.

Contraindications

Hypersensitivity. Co-administration w/ ganciclovir or valganciclovir.

Click to view Livtencity detailed prescribing information

Special Precautions

Not expected to be effective in treating CMV CNS infections (eg, meningo-encephalitis, retinitis). Virologic failure during treatment & relapse post-treatment (w/in 4-8 wk after treatment discontinuation). Monitor CMV DNA levels & check for resistance if patient is unresponsive to treatment. Concomitant use w/ immunosuppressants; frequently monitor immunosuppressant drug levels throughout treatment, especially following initiation & after discontinuation. ESRD, including patients on dialysis. Severe hepatic impairment (Child-Pugh Class C). Not recommended during pregnancy & in women of childbearing potential not using contraception. Discontinue breast-feeding during treatment. Paed <12 yr.

Click to view Livtencity detailed prescribing information

Use In Pregnancy & Lactation

Click to view Livtencity detailed prescribing information

Adverse Reactions

Taste disturbance; diarrhoea, nausea, vomiting; fatigue. Headache; upper abdominal pain; decreased appetite; increased immunosuppressant drug level, decreased wt.

Click to view Livtencity detailed prescribing information

Drug Interactions

Decreased plasma conc w/ strong CYP3A inducers eg, rifampicin, rifabutin, & St. John's wort; strong or moderate CYP3A inducers (carbamazepine, phenobarb, & phenytoin). Decreased efficacy w/ rifabutin & rifampin. Increased plasma conc w/ CYP3A inhibitors. Antagonized effect of ganciclovir & valganciclovir. Increased plasma conc of immunosuppressants (eg, tacrolimus, cyclosporin, everolimus, or sirolimus); HMG-CoA reductase inhibitors (eg, rosuvastatin); digoxin.

Click to view Livtencity detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Livtencity detailed prescribing information

Storage

View Livtencity storage conditions for details to ensure optimal shelf-life.

Description

View Livtencity description for details of the chemical structure and excipients (inactive components).

Action

View Livtencity mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antivirals

ATC Classification

J05AX10 - maribavir ; Belongs to the class of other antivirals. Used as a direct acting antiviral in the systemic treatment of viral infections.

Thai FDA Category

Presentation/Packing

Form

Livtencity FC tab 200 mg

Packing/Price

28's

Livtencity

Manufacturer:

Takeda

Distributor:

Zuellig Pharma